Sonnet BioTherapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Sonnet BioTherapeutics Holdings has been growing earnings at an average annual rate of 4.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 2.1% per year.
Key information
4.6%
Earnings growth rate
47.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 2.1% |
| Return on equity | -562.1% |
| Net Margin | -11,193.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement
Oct 04Sonnet BioTherapeutics announces 1-for-14 reverse stock split
Sep 16Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia
Jul 22We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate
Dec 19
Sonnet Bio issued U.S. patent for its albumin binding technology
Jun 08Sonnet shares rise after completing licensing agreement with New Life Therapeutics
May 03Sonnet BioTherapeutics reports FY results
Dec 17Revenue & Expenses BreakdownBeta
How Sonnet BioTherapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -14 | 6 | 0 |
| 30 Sep 23 | 0 | -19 | 7 | 0 |
| 30 Jun 23 | 0 | -23 | 8 | 0 |
| 31 Mar 23 | 0 | -27 | 8 | 0 |
| 31 Dec 22 | 0 | -29 | 8 | 0 |
| 30 Sep 22 | 0 | -30 | 9 | 0 |
| 30 Jun 22 | 1 | -29 | 9 | 0 |
| 31 Mar 22 | 1 | -27 | 9 | 0 |
| 31 Dec 21 | 1 | -25 | 9 | 0 |
| 30 Sep 21 | 0 | -25 | 9 | 0 |
| 30 Jun 21 | 0 | -67 | 9 | -5 |
| 31 Mar 21 | 0 | -73 | 9 | -3 |
| 31 Dec 20 | 0 | -69 | 8 | -1 |
| 30 Sep 20 | 0 | -66 | 8 | 0 |
| 30 Jun 20 | 0 | -20 | 6 | 7 |
| 31 Mar 20 | 0 | -9 | 5 | 5 |
| 31 Dec 19 | 0 | -7 | 3 | 4 |
| 30 Sep 19 | 0 | -5 | 3 | 2 |
Quality Earnings: SONN is currently unprofitable.
Growing Profit Margin: SONN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SONN is unprofitable, but has reduced losses over the past 5 years at a rate of 4.6% per year.
Accelerating Growth: Unable to compare SONN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SONN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: SONN has a negative Return on Equity (-562.07%), as it is currently unprofitable.